“…Based on the observation that the descriptive epidemiology of prostate cancer resembles that of vitamin D insufficiency, Schwartz and Hulka (1990) proposed that vitamin D maintained the differentiated phenotype of prostate cells and that low levels of vitamin D increase the risk for prostate cancer. Many subsequent epidemiologic (Ahonen et al, 2000;Luscombe et al, 2001) and laboratory studies (Feldman et al, 2000) have supported this hypothesis. For example,1a,25(OH) analogues exhibit significant growth-inhibitory, proapoptotic, anti-invasive and antimetastatic effects on prostate tumour cell lines in vitro and in vivo (Miller et al, 1992;Peehl et al, 1994;Schwartz et al, 1995Schwartz et al, , 1997Skowronski et al, 1995;Asou et al, 1998;Lokeshwar et al, 1999;Blutt et al, 2000;Seol et al, 2000).…”